Research suggests that GLP-1 drugs, such as Ozempic and Wegovy, may be associated with a lower risk of breast cancer. Some studies indicate that the risk may be reduced by as much as 30%. Further investigation, including a planned clinical trial, is expected to provide more information on the potential link between GLP-1 medications and breast cancer risk.